<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="ipa" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">ipa</book-part-id>
      <title-group>
        <title>
<italic toggle="yes">AIP</italic>-Related Familial Isolated Pituitary Adenomas</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Korbonits</surname>
            <given-names>M&#x000e1;rta</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>m.korbonits@qmul.ac.uk</email>
          <aff>Department of Endocrinology<break/>Barts and the London School of Medicine<break/>Queen Mary University of London<break/>London, United Kingdom</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kumar</surname>
            <given-names>Ajith V</given-names>
          </name>
          <degrees>MD</degrees>
          <email>ajith.kumar@gosh.nhs.uk</email>
          <aff>Clinical Genetics Unit<break/>North East Thames Regional Genetics Service<break/>Great Ormond Street Hospital<break/>London, United Kingdom</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2012-06-21" date-type="created">
          <day>21</day>
          <month>6</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="adnp-dis" document-type="chapter"><italic toggle="yes">ADNP-</italic>Related Intellectual Disability and Autism Spectrum Disorder</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="alk-nbs" document-type="chapter">
<italic toggle="yes">ALK</italic>-Related Neuroblastic Tumor Susceptibility</related-object>
      <abstract id="ipa.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">AIP</italic>-related isolated familial pituitary adenoma (<italic toggle="yes">AIP</italic>-related FIPA) is defined as the presence of an <italic toggle="yes">AIP</italic> germline pathogenic variant in an individual with a pituitary adenoma (regardless of family history).</p>
          <p>The most commonly occurring pituitary adenomas in this disorder are growth hormone-secreting adenomas (somatotropinoma), followed by prolactin-secreting adenomas (prolactinoma), growth hormone and prolactin co-secreting adenomas (somatomammotropinoma), and non-functioning pituitary adenomas (NFPA). Rarely TSH- or ACTH-secreting adenomas (thyrotropinoma and corticotropinoma) are observed. Clinical findings result from excess hormone secretion, lack of hormone secretion, and/or mass effects (e.g., headaches, visual field loss). Within the same family, pituitary adenomas can be of the same or different type. Age of onset in <italic toggle="yes">AIP</italic>-related FIPA is around 20-24 years (age range: 6-66 years).</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of <italic toggle="yes">AIP</italic>-related FIPA relies on identification of characteristic pituitary adenomas based on hormone secretion, pituitary MRI, and histologic findings, and identification of a heterozygous <italic toggle="yes">AIP</italic> pathogenic variant in an affected family member<italic toggle="yes">.</italic></p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Pituitary adenomas identified in those with <italic toggle="yes">AIP</italic>-related FIPA are treated in the same manner as pituitary adenomas of unknown cause: they can be treated by surgery, medical therapy (somatostatin analogs, growth hormone receptor antagonists, and dopamine agonists), and/or radiotherapy. Although surgery is usually performed in persons with <italic toggle="yes">AIP</italic>-related FIPA, it often does not fully control the tumor; thus, medical therapy and radiotherapy following surgery may be required to control hormone output and tumor growth.</p>
          <p><italic toggle="yes">Surveillance:</italic> Persons with <italic toggle="yes">AIP</italic>-related FIPA who have had a pituitary adenoma need to be followed for both recurrence of a treated adenoma and development of new adenomas. No specific guidelines exist; the authors&#x02019; recommendations are:</p>
          <list list-type="bullet">
            <list-item>
              <p>Yearly clinical assessment and pituitary function tests (IGF-1, spot GH, prolactin, LH/FSH, estradiol/testosterone, TSH, fT4, and morning cortisol);</p>
            </list-item>
            <list-item>
              <p>Dynamic testing to evaluate for hormone excess or deficiency (e.g., glucose tolerance test, insulin tolerance test) as needed; and</p>
            </list-item>
            <list-item>
              <p>Follow-up pituitary MRI, with frequency depending on clinical status, previous extent of the tumor, and treatment modality.</p>
            </list-item>
          </list>
          <p>Clinical monitoring of secondary complications of the tumor and/or its treatment (e.g., diabetes mellitus, hypertension, osteoarthritis, hypogonadism, osteoporosis) are necessary.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Family members at risk for <italic toggle="yes">AIP</italic>-related FIPA warrant molecular genetic testing for the family-specific pathogenic variant to identify those who harbor the variant and thus require surveillance over time for pituitary adenomas.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">AIP</italic>-related FIPA is inherited in an autosomal dominant manner. Each child of an individual with <italic toggle="yes">AIP</italic>-related FIPA has a 50% chance of inheriting the pathogenic variant. Prenatal diagnosis for pregnancies at increased risk is possible if the <italic toggle="yes">AIP</italic> pathogenic variant of an affected family member has been identified; however, requests for prenatal testing for conditions which (like FIPA) do not affect intellect and have some treatment available are rare. Furthermore, as <italic toggle="yes">AIP</italic>-related FIPA demonstrates reduced penetrance, the finding of a <italic toggle="yes">AIP</italic> pathogenic variant prenatally does not allow accurate prediction of whether a tumor will develop, the adenoma type, age of onset, prognosis, availability of and/or outcome of treatment.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="ipa.Diagnosis">
        <title>Diagnosis</title>
        <p><italic toggle="yes">AIP</italic>-related isolated familial pituitary adenoma (<italic toggle="yes">AIP</italic>-related FIPA) is defined as the presence of an <italic toggle="yes">AIP</italic> germline pathogenic variant in an individual with a pituitary adenoma (regardless of family history).</p>
        <p>The pituitary adenomas can be:</p>
        <list list-type="bullet">
          <list-item>
            <p>Growth hormone-secreting (somatotropinoma)</p>
          </list-item>
          <list-item>
            <p>Prolactin-secreting (prolactinoma)</p>
          </list-item>
          <list-item>
            <p>Growth hormone and prolactin co-secreting (somatomammotropinoma)</p>
          </list-item>
          <list-item>
            <p>Non-functioning pituitary adenoma (NFPA)</p>
          </list-item>
          <list-item>
            <p>TSH- or ACTH-secreting (thyrotropinoma and corticotropinoma). Note: These are rare; thyrotropinoma has been observed in one person with an <italic toggle="yes">AIP</italic> pathogenic variant.</p>
          </list-item>
          <list-item>
            <p>Multi-hormonal (i.e., secreting more than one pituitary hormone)</p>
          </list-item>
        </list>
        <sec id="ipa.Testing">
          <title>Testing</title>
          <p>Pituitary adenomas can be categorized by cell-type origin, hormone secreting activity, and/or size. Tumors smaller than 10 mm in diameter are considered microadenomas; tumors larger than 10 mm in diameter are considered macroadenomas. Virtually all pituitary tumors are benign adenomas; pituitary carcinomas are very rare. Despite the benign histologic nature of the pituitary adenomas they can cause morbidity through hormone dysfunction and/or mass effects (i.e., the tumor compression syndrome).</p>
          <p>The diagnostic changes in hormone secretion, findings on imaging, and histology of each tumor type are reviewed in <italic toggle="yes">Endocrinology</italic> [<xref ref-type="bibr" rid="ipa.REF.de_groot.2010">De Groot &#x00026; Jameson 2010</xref>]. The following is a brief summary.</p>
          <p>
            <bold>Somatotropinoma</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Growth hormone (GH) secretion.</bold> The diagnostic test for somatotropinoma is an oral glucose tolerance test (oGTT) using 75 mg glucose. Controls fully suppress GH secretion to undetectable levels, whereas persons with a somatotropinoma fail to suppress growth hormone below 1 mU/L; some show a paradoxical increase in growth hormone concentration [<xref ref-type="bibr" rid="ipa.REF.katznelson.2011">Katznelson et al 2011</xref>]. Note: (1) IGF-1 levels are invariably high in individuals with severe untreated somatotropinoma; however, divergent GH and IGF-I values may be seen in up to 30% of patients: the most common discrepancy is an elevated IGF-I level with a normal GH value, thought to reflect earlier disease. Of note, age-related IGF-1 normal ranges need to be used to interpret test results. (2) The diagnosis of somatotropinoma can be difficult to establish in adolescents: during peak growth velocity GH levels can be high and not fully suppressed during oGTT; IGF-1 levels range widely and can vary by stage of puberty. False-positive responses to the oGTT may also be seen in patients with diabetes mellitus, liver disease, renal disease, or anorexia nervosa.(3) About half of <italic toggle="yes">AIP</italic> mutation-positive GH-secreting pituitary adenomas co-secrete prolactin, which may be due to co-secretion and/or the &#x02018;stalk effect&#x02019; (i.e., high hormone levels that result from compression of the pituitary stalk and decreased inhibitory dopaminergic input). (4) Deficiency of other pituitary hormones is often seen in macroadenomas.</p>
            </list-item>
            <list-item>
              <p><bold>Imaging.</bold> Contrast-enhanced pituitary MRI is the imaging modality of choice. By the time they cause symptoms and biochemical abnormalities, the overwhelming majority of somatotropinomas are macroadenomas and are sufficiently large to be detected by MRI; however, tumors may not be detectable in their early stages. Note: With modern imaging techniques and contrast agents, tumors as small as 2 mm can be identified.</p>
            </list-item>
            <list-item>
              <p><bold>Histology.</bold> Immunostaining for growth hormone is usually positive in somatotropinomas. Immunostaining for prolactin is often positive with or without clinical or biochemical hyperprolactinemia. In somatomammotropinomas both GH and PRL staining are positive. Somatotropinomas can be classified into sparsely and densely granulated adenomas using electron microscopy or a cytokeratin stain (e.g., Cam5.2 or CK8). Persons with <italic toggle="yes">AIP</italic>-related FIPA often have sparsely granulated adenomas. Somatotroph (growth hormone-secreting) cell hyperplasia has been described in a few cases of <italic toggle="yes">AIP</italic>-related FIPA and acromegaly. Note: Somatotroph cell hyperplasia can be distinguished from somatotropinoma by reticulin staining.</p>
            </list-item>
          </list>
          <p>
            <bold>Prolactinoma</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Prolactin (PRL)</bold>
<bold>secretion.</bold> PRL concentration can be assessed from a random serum sample. Note: (1) Due to common interference of assays for prolactin with macroprolactin, it is important for the laboratory to perform PEG (polyethylene glycol) precipitation at the initial assessment. (2) Macroprolactinomas can be associated with paradoxically normal or only slightly elevated levels of prolactin as a result of the hook effect (i.e., falsely low values on the prolactin immunoassay in the presence of an overwhelming amount of antigen [prolactin] that affects the binding capacity of the added antibody). (3) Some of the numerous causes of hyperprolactinemia without pituitary adenoma include: pregnancy, lactation, exercise, stress, certain drugs, and polycystic ovary syndrome. Pituitary lesions that do not produce prolactin can also cause high prolactin levels due to the stalk effect. (4) About half of the <italic toggle="yes">AIP</italic>-mutation positive GH-secreting pituitary adenomas co-secrete prolactin.</p>
            </list-item>
            <list-item>
              <p><bold>Imaging.</bold> Contrast-enhanced pituitary MRI is the imaging modality of choice. Sometimes pituitary microadenomas too small to be detected on MRI can cause elevated serum concentrations of prolactin. With modern imaging techniques and contrast agent, tumors as small as 2 mm can be identified. The overwhelming majority of prolactinomas in persons with a germline <italic toggle="yes">AIP</italic> pathogenic variant are macroadenomas.</p>
            </list-item>
            <list-item>
              <p><bold>Histology.</bold> Immunostaining for prolactin is usually positive. In somatomammotropinomas both GH and PRL staining are positive.</p>
            </list-item>
          </list>
          <p>
            <bold>Non-functioning pituitary adenoma (NFPA)</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Hormone secretion</bold>. By definition, no clinically relevant increase in hormone secretion is observed; however, low-level increases in FSH secretion can be observed.</p>
            </list-item>
            <list-item>
              <p><bold>Imaging.</bold> Contrast-enhanced pituitary MRI detects clinically relevant NFPAs.</p>
            </list-item>
            <list-item>
              <p><bold>Histology</bold>. More than 95% of NFPAs are of gonadotroph origin; immunostaining for LH/FSH can be observed in scattered cells.</p>
              <list list-type="bullet">
                <list-item>
                  <p>&#x02018;Null&#x02019; adenomas are those in which no immunostaining for any pituitary hormones is evident.</p>
                </list-item>
                <list-item>
                  <p>&#x0201c;Silent&#x0201d; ACTH, GH, or GH and PRL adenomas (i.e., non-functioning adenomas in which immunostaining is positive for ACTH, GH, or PRL) have been described in persons with a germline <italic toggle="yes">AIP</italic> pathogenic variant.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>
            <bold>Thyrotropinoma</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>TSH secretion</bold>. Serum concentrations of TSH are normal or high in the presence of elevated total and/or free thyroid hormone concentrations. Note: Measurement of markers of peripheral thyroid hormone action and dynamic tests of thyroid function may distinguish a thyrotropinoma from the syndrome of resistance to thyroid hormone.</p>
            </list-item>
            <list-item>
              <p><bold>Imaging</bold>. Contrast-enhanced pituitary MRI is the imaging modality of choice. Thyrotropinomas are often, but not always, macroadenomas.</p>
            </list-item>
          </list>
          <p>
            <bold>Corticotropinoma</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>ACTH secretion</bold>. The diagnosis of Cushing disease can be difficult and may require dynamic testing, abnormal circadian rhythm, and sometimes petrosal sampling.</p>
            </list-item>
            <list-item>
              <p><bold>Imaging</bold>. Contrast-enhanced pituitary MRI is the imaging modality of choice.</p>
            </list-item>
            <list-item>
              <p><bold>Histology</bold>. Immunostaining for ACTH is observed in most cases; Crook&#x02019;s change (hyalinization) can be observed in some.</p>
            </list-item>
          </list>
          <sec id="ipa.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold> By definition <italic toggle="yes">AIP</italic> is the only gene in which mutation causes <italic toggle="yes">AIP</italic>-related familial isolated pituitary adenomas.</p>
            <table-wrap id="ipa.T.summary_of_molecular_genetic_testi" position="anchor" orientation="portrait">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in <italic toggle="yes">AIP</italic>-Related Familial Isolated Pituitary Adenomas</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ipa.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_ipa.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_ipa.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Allelic Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_ipa.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mutation Detection Frequency by Test Method&#x000a0;<sup>1</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ipa.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">AIP</italic>
                    </td>
                    <td headers="hd_h_ipa.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_ipa.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_ipa.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">~90%&#x000a0;<sup>6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ipa.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>7,&#x000a0;8</sup></td>
                    <td headers="hd_h_ipa.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon or whole-gene deletions</td>
                    <td headers="hd_h_ipa.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">~10%</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="ipa.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="ipa" object-id="ipa.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="ipa.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="ipa.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="ipa.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a pathogenic variant that is present in the indicated gene</p>
                </fn>
                <fn id="ipa.TF.1.4">
                  <label>4. </label>
                  <p>Examples of variants detected by sequence analysis may include small intragenic deletions/insertions and pathogenic missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="ipa.TF.1.5">
                  <label>5. </label>
                  <p>One promoter variant has been reported. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="ipa-Table4.pdf" content-type="local-data">Table 4</inline-supplementary-material> (pdf).</p>
                </fn>
                <fn id="ipa.TF.1.6">
                  <label>6. </label>
                  <p><xref ref-type="bibr" rid="ipa.REF.georgitsi.2008b.4146">Georgitsi et al [2008b]</xref>, <xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al [2010]</xref></p>
                </fn>
                <fn id="ipa.TF.1.7">
                  <label>7. </label>
                  <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="ipa.TF.1.8">
                  <label>8. </label>
                  <p>If laboratories are using commercial MLPA kits, the probes for <italic toggle="yes">AIP</italic> are typically combined with the probes for <italic toggle="yes">MEN1</italic> (see <related-object link-type="booklink" source-id="gene" document-id="men1" document-type="chapter">Multiple Endocrine Neoplasia Type 1</related-object>); such kits can detect deletions or duplications in both genes.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="ipa.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis of <italic toggle="yes">AIP</italic>-related FIPA</bold>
<bold>in a proband.</bold> Individuals with a pituitary adenoma in whom molecular genetic testing for an <italic toggle="yes">AIP</italic> germline pathogenic variant should be considered are those who do not have a clinical diagnosis or features of a recognized syndrome or a pathogenic variant in one of the genes known to cause <related-object link-type="booklink" source-id="gene" document-id="men1" document-type="chapter">multiple endocrine neoplasia type 1</related-object> or type 4 (<italic toggle="yes">MEN1</italic> or <italic toggle="yes">MEN4</italic>) or <related-object link-type="booklink" source-id="gene" document-id="carney" document-type="chapter">Carney complex</related-object>, and who have <bold>one or more</bold> of the following [<xref ref-type="bibr" rid="ipa.REF.korbonits.2012.351">Korbonits et al 2012</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>A family history of more than one individual with a pituitary tumor [<xref ref-type="bibr" rid="ipa.REF.vierimaa.2006.1228">Vierimaa et al 2006</xref>]A germline <italic toggle="yes">AIP</italic> pathogenic variant is identified in approximately 20% of families with FIPA [<xref ref-type="bibr" rid="ipa.REF.chahal.2010.419">Chahal et al 2010</xref>] and in 40% of families in which somatotroph adenomas are the only tumor type observed. Note: To date, <italic toggle="yes">AIP</italic> pathogenic variants have not been identified in families with two adults with microprolactinomas; therefore, the probability of identifying an <italic toggle="yes">AIP</italic> pathogenic variant in such a family is low.</p>
            </list-item>
            <list-item>
              <p>Pituitary adenoma diagnosed before age 18 yearsA germline <italic toggle="yes">AIP</italic> pathogenic variant is identified in approximately 20% of simplex cases of childhood-onset somatotroph adenoma [<xref ref-type="bibr" rid="ipa.REF.chahal.2010.419">Chahal et al 2010</xref>, <xref ref-type="bibr" rid="ipa.REF.cazabat.2011.1973">Cazabat et al 2011</xref>, <xref ref-type="bibr" rid="ipa.REF.tichomirowa.2011.509">Tichomirowa et al 2011</xref>].Note: The apparent absence of a family history in such individuals could result from reduced penetrance or lack of information about the family. A d<italic toggle="yes">e novo</italic> pathogenic variant has been described in one individual [<xref ref-type="bibr" rid="ipa.REF.stratakis.2010.457">Stratakis et al 2010</xref>].</p>
            </list-item>
            <list-item>
              <p>No apparent family history of pituitary adenomas and <bold>one</bold> of the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p>A pituitary macroadenoma diagnosed before age 30 years [<xref ref-type="bibr" rid="ipa.REF.tichomirowa.2011.509">Tichomirowa et al 2011</xref>], especially a growth hormone-secreting pituitary tumor [<xref ref-type="bibr" rid="ipa.REF.cazabat.2007.1">Cazabat et al 2007</xref>, <xref ref-type="bibr" rid="ipa.REF.georgitsi.2008a.621">Georgitsi et al 2008a</xref>, <xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al 2010</xref>]</p>
                </list-item>
                <list-item>
                  <p>A prolactin-secreting macroadenoma [<xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al 2010</xref>, <xref ref-type="bibr" rid="ipa.REF.cazabat.2011.1973">Cazabat et al 2011</xref>]A germline <italic toggle="yes">AIP</italic> pathogenic variant is identified in 11% of simplex cases (i.e., no apparent family history of pituitary adenomas) of young-onset (age &#x0003c;30 yrs) pituitary macroadenomas [<xref ref-type="bibr" rid="ipa.REF.tichomirowa.2011.509">Tichomirowa et al 2011</xref>].</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>The molecular genetic testing strategy for <italic toggle="yes">AIP</italic> germline pathogenic variants is:</p>
          <list list-type="order">
            <list-item>
              <label>1</label>
              <p>Perform sequence analysis.</p>
            </list-item>
            <list-item>
              <label>2</label>
              <p>If no pathogenic variant is identified by sequence analysis, perform deletion/duplication testing.</p>
            </list-item>
          </list>
          <p><bold>Predictive testing</bold> for at-risk asymptomatic family members requires prior identification of the pathogenic variant in the family.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variant in the family.</p>
        </sec>
      </sec>
      <sec id="ipa.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="ipa.Clinical_Description">
          <title>Clinical Description</title>
          <p>The most common pituitary adenomas observed in <italic toggle="yes">AIP</italic>-related familial isolated pituitary adenoma (<italic toggle="yes">AIP-</italic>related FIPA) are somatotropinoma (growth hormone-secreting), followed by somatomammotropinoma (growth hormone- and prolactin-secreting) and prolactinoma (prolactin-secreting) [<xref ref-type="bibr" rid="ipa.REF.vierimaa.2006.1228">Vierimaa et al 2006</xref>, <xref ref-type="bibr" rid="ipa.REF.daly.2007.1891">Daly et al 2007</xref>, <xref ref-type="bibr" rid="ipa.REF.leontiou.2008.2390">Leontiou et al 2008</xref>]. Clinically non-functioning pituitary adenomas (NFPAs) are also identified. Rarely, TSH-secreting or ACTH-secreting adenomas have been identified.</p>
          <p>In the <xref ref-type="bibr" rid="ipa.REF.daly.2007.1891">Daly et al [2007]</xref> cohort, 36% had a GH adenoma, 42% had a PRL adenoma, 14% had NFPA, and 8% had an ACTH-, TSH- or FSH-oma. In the <xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al [2010]</xref> study, 68% had a GH or mixed GH/PRL adenoma, 20% had PRL adenoma, 11% had NFPA, and 1% had ACTH-, TSH-, or FSH-oma. Of note, within the same family different relatives with the same <italic toggle="yes">AIP</italic> pathogenic variant can have different types of adenomas.</p>
          <p>The following is true of <italic toggle="yes">AIP-</italic>related FIPA as well as all types of pituitary adenomas. Histologically, pituitary adenomas are benign; however, because of their hormonal activity, location, size, and proximity to important structures, the prognosis depends on the stage of the tumor at diagnosis; the morbidity of tumors diagnosed at an advanced stage (i.e., with invasion of surrounding structures) tends to be high.</p>
          <p>The median age of diagnosis of <italic toggle="yes">AIP-</italic>related FIPA is 23 years. The earliest age of diagnosis of a pituitary tumor in a person with an <italic toggle="yes">AIP</italic> pathogenic variant is six years; the oldest is 78 years [<xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al 2010</xref>, <xref ref-type="bibr" rid="ipa.REF.chahal.2011.43">Chahal et al 2011</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>In 20 families with an <italic toggle="yes">AIP</italic> pathogenic variant, 16 had at least one member with pituitary gigantism (i.e., childhood-onset somatotropinoma) and/or disease onset before age 18 years, while only three of the 44 families with FIPA who did not have an <italic toggle="yes">AIP</italic> pathogenic variant had a member with pituitary gigantism and/or disease onset before age 18 years [<xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al 2010</xref>].</p>
            </list-item>
            <list-item>
              <p>Of 75 persons who had an <italic toggle="yes">AIP</italic> germline pathogenic variant, over 52% had childhood- or adolescent-onset somatotropinoma; 4% of persons who were simplex cases without an <italic toggle="yes">AIP</italic> pathogenic variant had a somatotropinoma [<xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al 2010</xref>].</p>
            </list-item>
          </list>
          <sec id="ipa.Hormone_Dysfunction">
            <title>Hormone Dysfunction</title>
            <p><bold>Somatotropinoma</bold> (growth hormone-secreting pituitary adenoma)</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Acromegaly</bold>. Approximately 80%-85% of persons with <italic toggle="yes">AIP</italic>-related FIPA have acromegaly. Persons with acromegaly have excess growth hormone secretion resulting in enlargement of the hands and feet, and coarse facial appearance with prognathism and malocclusion of the teeth. They may have headaches, joint pain, carpal tunnel syndrome, sleeping difficulties, excessive sweating, hypertension, diabetes mellitus, and muscle weakness. Individuals with acromegaly of any cause are at increased risk for colon cancer.If acromegaly starts in childhood/adolescence it can lead to pituitary gigantism (see following).</p>
              </list-item>
              <list-item>
                <p><bold>Pituitary gigantism</bold>. Excessive growth hormone secretion before the fusion of the growth plates results in pituitary gigantism. Exceptionally tall stature results from a combination of high GH levels and delayed onset of puberty due to suppression of LH/FSH secretion by mass effect of the tumor and/or, when present, the direct effect of high prolactin levels. One third of all individuals with a germline <italic toggle="yes">AIP</italic> pathogenic variant and 40%-50% of persons with an <italic toggle="yes">AIP</italic> mutation-positive GH-secreting adenoma have pituitary gigantism [<xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al 2010</xref>].</p>
              </list-item>
            </list>
            <p><bold>Prolactinomas.</bold> Approximately 10%-15% of persons with an <italic toggle="yes">AIP</italic> pathogenic variant have a prolactinoma [<xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al 2010</xref>, <xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al 2010</xref>]. Prolactinomas result in signs and symptoms of prolactin excess (i.e., amenorrhea, sexual problems, galactorrhea, and infertility) and can also cause mass effects (e.g., visual field defects, headaches).</p>
            <p>Almost all <italic toggle="yes">AIP</italic> mutation-related prolactinomas are macroadenomas with male predominance [<xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al 2010</xref>, <xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al 2010</xref>]. In contrast, prolactinomas in affected families without an <italic toggle="yes">AIP</italic> pathogenic variant can be both macro- and microadenomas</p>
            <p><bold>Non-functioning pituitary adenomas (NFPAs).</bold> NFPAs are seen in 4%-7% of persons with an <italic toggle="yes">AIP</italic> pathogenic variant.</p>
            <p>NFPAs are usually diagnosed due to the local effects of the tumor, such as bitemporal hemianopia or hypogonadism. It is unclear why these silent adenomas do not release hormones at a clinically recognizable level; however, there is likely to be a continuum between fully functional and completely silent adenomas. Distinguishing NFPA from prolactinomas can occasionally be difficult due to the stalk effect.</p>
            <p>In <italic toggle="yes">AIP</italic>-related FIPA NFPAs are often (but not always) silent somatotroph or lactotroph adenomas [<xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al 2010</xref>, <xref ref-type="bibr" rid="ipa.REF.villa.2011.347">Villa et al 2011</xref>]. In families with <italic toggle="yes">AIP</italic>-related FIPA, NFPAs are identified at a younger age than NFPAs in persons without a germline pathogenic variant [<xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al 2010</xref>].</p>
            <p>Note: NFPAs are more common in families with FIPA without an <italic toggle="yes">AIP</italic> pathogenic variant than in families with <italic toggle="yes">AIP-</italic>related FIPA. NFPAs in families with FIPA who do not have an <italic toggle="yes">AIP</italic> pathogenic variant are most often silent gonadotroph adenomas.</p>
            <p><bold>TSH-secreting adenomas</bold> (causing hyperthyroidism) and <bold>ACTH-secreting adenomas</bold> (causing Cushing disease) are rarely seen in FIPA.</p>
            <p>A single individual with <italic toggle="yes">AIP</italic>-related FIPA and a thyrotropinoma, and a single individual with FIPA, a thyrotropinoma, and no pathogenic variant in <italic toggle="yes">AIP</italic> have been described [<xref ref-type="bibr" rid="ipa.REF.daly.2007.1891">Daly et al 2007</xref>, <xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al 2010</xref>].</p>
            <p>Two simplex cases with <italic toggle="yes">AIP</italic>-related FIPA with Cushing disease have been described. Of 74 children with Cushing disease, the one child found to harbor an <italic toggle="yes">AIP</italic> pathogenic variant had an aggressive tumor [<xref ref-type="bibr" rid="ipa.REF.stratakis.2010.457">Stratakis et al 2010</xref>]. Another individual with Cushing disease was described by <xref ref-type="bibr" rid="ipa.REF.georgitsi.2007a.4101">Georgitsi et al [2007a]</xref>.</p>
            <p>Note: A few families with homogeneous pituitary adenoma phenotypes (i.e., pituitary tumors of the same type) and heterogeneous phenotypes (i.e., pituitary tumors of different types) with FIPA without an <italic toggle="yes">AIP</italic> pathogenic variant with Cushing disease have been described [<xref ref-type="bibr" rid="ipa.REF.daly.2007.1891">Daly et al 2007</xref>, <xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al 2010</xref>].</p>
            <p><bold>Other.</bold> Subfertility is common in persons with pituitary tumors. No data are available specifically regarding subfertility in <italic toggle="yes">AIP</italic>-related FIPA.</p>
            <p><bold>Mass effects</bold>. Large pituitary adenomas can be associated with deficiencies of other pituitary hormones that result in subfertility, hypothyroidism, hypoadrenalism, low levels of growth hormone, and panhypopituitarism.</p>
            <p>Macroadenomas (&#x0003e;10 mm diameter) may also press on the optic chiasm and optic tracts causing bitemporal hemianopia. The tumor may invade the adjacent cavernous sinus. Headache can be present in any type of adenoma but is especially common in acromegaly; the mechanism for the increased frequency is unknown.</p>
            <p>Larger pituitary tumors may autoinfarct, resulting in pituitary apoplexy (sudden-onset severe headache, visual disturbance, cranial nerve palsies, hypoglycemia, and hypotensive shock). Pituitary apoplexy has been described in individuals with <italic toggle="yes">AIP</italic>-related FIPA [<xref ref-type="bibr" rid="ipa.REF.chahal.2011.43">Chahal et al 2011</xref>].</p>
            <p><bold>Pituitary carcinoma</bold>. To date pituitary carcinoma has not been described in an individual with <italic toggle="yes">AIP</italic>-related FIPA.</p>
            <p><bold>Other, non-pituitary tumors</bold> have been observed in some families with <italic toggle="yes">AIP</italic>-related FIPA; however, because the background population risk for tumors is fairly high and because no consistent pattern has been observed, at present there is no conclusive evidence that an <italic toggle="yes">AIP</italic> germline pathogenic variant increases the risk for any other tumors.</p>
          </sec>
        </sec>
        <sec id="ipa.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The question of genotype-phenotype correlation in <italic toggle="yes">AIP</italic>-related FIPA is controversial. The majority (70%) of <italic toggle="yes">AIP</italic> variants result in a truncated protein.</p>
          <list list-type="bullet">
            <list-item>
              <p>Some have suggested that individuals with an <italic toggle="yes">AIP</italic> pathogenic variant resulting in a truncated protein manifest symptoms at a significantly younger age than those with a pathogenic variant that preserves the structure of the C-terminal end of the protein (22.7 +/- 9.6 vs. 29.8 +/- 10.9 years, respectively) [<xref ref-type="bibr" rid="ipa.REF.cazabat.2009.132">Cazabat et al 2009</xref>]; however, data from the two largest cohorts of those with <italic toggle="yes">AIP</italic>-related FIPA do not support this finding [<xref ref-type="bibr" rid="ipa.REF.cain.2010.681">Cain et al 2010</xref>, <xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al 2010</xref>].</p>
            </list-item>
            <list-item>
              <p>Penetrance was no higher in persons with a pathogenic truncating variant than in those with a non-truncating variant [<xref ref-type="bibr" rid="ipa.REF.cain.2010.681">Cain et al 2010</xref>, <xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al 2010</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="ipa.Penetrance">
          <title>Penetrance</title>
          <p>Studies on large families with <italic toggle="yes">AIP</italic> pathogenic variants show a clinical penetrance of pituitary tumors of approximately 15%-30% [<xref ref-type="bibr" rid="ipa.REF.vierimaa.2006.1228">Vierimaa et al 2006</xref>, <xref ref-type="bibr" rid="ipa.REF.naves.2007.383">Naves et al 2007</xref>, <xref ref-type="bibr" rid="ipa.REF.chahal.2011.43">Chahal et al 2011</xref>]. Although some families with <italic toggle="yes">AIP-</italic>related FIPA can show high penetrance, the higher levels of penetrance initially reported in some families is probably ascertainment bias due to insufficient information on all at-risk family members (e.g., lack of medical records, information on pituitary hormone testing, and/or imaging studies) [<xref ref-type="bibr" rid="ipa.REF.daly.2007.1891">Daly et al 2007</xref>, <xref ref-type="bibr" rid="ipa.REF.leontiou.2008.2390">Leontiou et al 2008</xref>].</p>
          <p>The factors influencing penetrance are not known; the possibility of a second locus has been investigated [<xref ref-type="bibr" rid="ipa.REF.khoo.2009.1057">Khoo et al 2009</xref>].</p>
        </sec>
        <sec id="ipa.Anticipation">
          <title>Anticipation</title>
          <p>Genetic anticipation is not observed in <italic toggle="yes">AIP</italic>-related FIPA. However, affected second- or third-generation family members may be diagnosed earlier than members of the first generation because of greater awareness of the disorder and, thus, earlier recognition of the significance of adenoma-related symptoms [<xref ref-type="bibr" rid="ipa.REF.daly.2006.4769">Daly et al 2006</xref>].</p>
        </sec>
        <sec id="ipa.Nomenclature">
          <title>Nomenclature</title>
          <p>Pituitary adenoma predisposition (PAP) syndrome is used to refer to those individuals who have an <italic toggle="yes">AIP</italic> pathogenic variant. See <xref ref-type="fig" rid="ipa.F1">Figure 1</xref>.</p>
        </sec>
        <sec id="ipa.Prevalence">
          <title>Prevalence</title>
          <p>The exact prevalence of <italic toggle="yes">AIP</italic>-related FIPA is not known. To date, about 50 families and about 50 simplex cases (i.e., a single occurrence in a family) of <italic toggle="yes">AIP</italic>-related FIPA have been identified [<xref ref-type="bibr" rid="ipa.REF.chahal.2010.419">Chahal et al 2010</xref>, <xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al 2010</xref>].</p>
        </sec>
      </sec>
      <sec id="ipa.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than <italic toggle="yes">AIP</italic>-related FIPA are known to be associated with mutation of <italic toggle="yes">AIP</italic>.</p>
      </sec>
      <sec id="ipa.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <sec id="ipa.Familial_Isolated_Pituitary_Adenoma">
          <title>Familial Isolated Pituitary Adenoma (FIPA)</title>
          <p>FIPA is defined as more than one member of a family with a pituitary adenoma and no other features of a syndrome known to be associated with pituitary adenomas. Except for those with pathogenic variants in <italic toggle="yes">AIP</italic>, a genetic cause has not yet been determined for the remainder of families with FIPA.</p>
          <p>Families with FIPA of known or unknown cause can have homogeneous pituitary adenoma phenotypes (i.e., pituitary tumors of the same type) or heterogeneous phenotypes (i.e., pituitary tumors of different types).</p>
          <p>Aspects of FIPA that tend to differ between families in which a germline <italic toggle="yes">AIP</italic> pathogenic variant has been identified and those in which no germline <italic toggle="yes">AIP</italic> pathogenic variant has been identified include: age of onset, number of persons affected in the family, male to female ratio, and typical adenoma types. Tumor variables may also include: size, aggressiveness, and response to treatment [<xref ref-type="bibr" rid="ipa.REF.chahal.2010.419">Chahal et al 2010</xref>]. (See <xref ref-type="table" rid="ipa.T.comparison_of_findings_in_persons">Table 2</xref>.)</p>
          <table-wrap id="ipa.T.comparison_of_findings_in_persons" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>Comparison of Findings in Persons with Pituitary Adenomas by Family History and Presence/Absence of a Germline <italic toggle="yes">AIP</italic> Pathogenic Variant</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" rowspan="2" valign="middle" colspan="2" align="left" scope="colgroup" headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1"/>
                  <th id="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2"><italic toggle="yes">AIP</italic>-Related FIPA</th>
                  <th id="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Non-<italic toggle="yes">AIP</italic> Related</th>
                </tr>
                <tr>
                  <th headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3" id="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">FIPA</th>
                  <th headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3" id="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Simplex Somatotropinoma&#x000a0;<sup>1</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Clinical Features</bold>
                  </td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Age of onset&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">18-24 years</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">40 years</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">43 years</td>
                </tr>
                <tr>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Average number affected family members&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">3-4</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">2-3</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">N/A</td>
                </tr>
                <tr>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Male to female ratio&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">2:1</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">1:1</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">1:1</td>
                </tr>
                <tr>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Adenoma Features</bold>
                  </td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Somatotropinomas / somatomammotropinomas</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">70%-80%</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">~50%</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">N/A</td>
                </tr>
                <tr>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Size</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Macroadenomas in vast majority</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">N/A</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Smaller</td>
                </tr>
                <tr>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Aggressiveness</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">More</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">N/A</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Less</td>
                </tr>
                <tr>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Response to treatment</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Poorer</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">N/A</td>
                  <td headers="hd_h_ipa.T.comparison_of_findings_in_persons_1_1_1_3 hd_h_ipa.T.comparison_of_findings_in_persons_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Better</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="ipa.TF.2.1">
                <label>1. </label>
                <p>Simplex case = a single occurrence in a family</p>
              </fn>
              <fn id="ipa.TF.2.2">
                <label>2. </label>
                <p><xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al [2010]</xref>, <xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al [2010]</xref></p>
              </fn>
              <fn id="ipa.TF.2.3">
                <label>3. </label>
                <p>
                  <xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al [2010]</xref>
                </p>
              </fn>
              <fn id="ipa.TF.2.4">
                <label>4. </label>
                <p><xref ref-type="bibr" rid="ipa.REF.cazabat.2009.132">Cazabat et al [2009]</xref>, <xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al [2010]</xref>, <xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al [2010]</xref></p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="ipa.Other_Causes_of_Pituitary_Tumors">
          <title>Other Causes of Pituitary Tumors</title>
          <p>In children more often than in adults, pituitary tumors may be a manifestation of a genetic condition. In addition to familial isolated pituitary adenoma, genetic conditions are multiple endocrine neoplasia type 1 and type 4, Carney complex, and McCune-Albright syndrome [<xref ref-type="bibr" rid="ipa.REF.keil.2008.563">Keil &#x00026; Stratakis 2008</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p><related-object link-type="booklink" source-id="gene" document-id="men1" document-type="chapter"><bold>Multiple endocrine neoplasia type 1</bold></related-object> (MEN1) includes varying combinations of more than 20 endocrine and non-endocrine tumors. Clinical diagnostic criteria for MEN1 include the presence of two endocrine tumors that are parathyroid, pituitary, or gastro-entero-pancreatic (GEP) tract tumors. The most common endocrine tumor in MEN1 is parathyroid adenoma, with nearly all affected individuals developing hypercalcemia by age 50 years. Pituitary tumors occur in about 40% of persons with MEN1, most often prolactinomas. Mutation of <italic toggle="yes">MEN1</italic> is causative; inheritance is autosomal dominant.</p>
            </list-item>
            <list-item>
              <p><bold>MEN1-like syndrome caused by mutation of <italic toggle="yes">CDKN1B</italic></bold> (encoding cyclin dependent kinase inhibitor 1B), also known as <bold>MEN4</bold>. The clinical findings are similar to those of MEN1. This syndrome has been reported in five families to date [<xref ref-type="bibr" rid="ipa.REF.pellegata.2006.15558">Pellegata et al 2006</xref>, <xref ref-type="bibr" rid="ipa.REF.georgitsi.2007b.3321">Georgitsi et al 2007b</xref>, <xref ref-type="bibr" rid="ipa.REF.agarwal.2009.1826">Agarwal et al 2009</xref>].</p>
            </list-item>
            <list-item>
              <p><related-object link-type="booklink" source-id="gene" document-id="carney" document-type="chapter"><bold>Carney complex</bold></related-object> is characterized by skin pigmentary abnormalities, myxomas of the heart and other organs, endocrine tumors or overactivity, and schwannomas. Primary pigmented nodular adrenocortical disease (PPNAD), which causes Cushing syndrome, is the most frequently observed endocrine tumor in Carney complex, occurring in approximately 25% of affected individuals. Large-cell calcifying Sertoli cell tumors (LCCSCTs) are observed in one third of affected males within the first decade and in almost all adult males. Up to 75% of individuals with Carney complex have multiple thyroid nodules. Although many affected individuals have somatotroph cell hyperplasia, true adenomas do not develop. Acromegaly has been reported in approximately 10% of adults. About 60% of Carney complex results from mutation of <italic toggle="yes">PRKAR1A</italic> (encoding protein kinase A1A regulatory subunit); inheritance is autosomal dominant.</p>
            </list-item>
            <list-item>
              <p><related-object link-type="booklink" source-id="gene" document-id="mccune-albright" document-type="chapter"><bold>McCune-Albright syndrome</bold></related-object> is characterized by polyostotic fibrous dysplasia, caf&#x000e9; au lait patches, and multiple endocrine disorders (e.g., multinodular goiters, multinodular adrenal hyperplasia, precocious puberty, and pituitary adenomas). Increased secretion of growth hormone and prolactin is common in persons with this disorder because of growth hormone-producing adenomas and nodular and diffuse hyperplasia of somatomammotroph cells, respectively [<xref ref-type="bibr" rid="ipa.REF.horvath.2008.1">Horvath &#x00026; Stratakis 2008</xref>]. Somatic mosaicism for pathogenic gain-of-function variants in <italic toggle="yes">GNAS</italic> (encoding guanine nucleotide-binding protein G(s) subunit alpha isoforms short) is causative; no familial cases have been reported.</p>
            </list-item>
          </list>
          <p><bold>Sporadic pituitary tumors.</bold> The incidence of symptomatic pituitary tumor in the general population is estimated at 1:1000 to 1:1300 [<xref ref-type="bibr" rid="ipa.REF.daly.2006.4769">Daly et al 2006</xref>, <xref ref-type="bibr" rid="ipa.REF.fernandez.2010.377">Fernandez et al 2010</xref>]. Autopsy and radiologic studies suggest that 14%-22% of the population may harbor a pituitary tumor, most of these being asymptomatic [<xref ref-type="bibr" rid="ipa.REF.ezzat.2004.613">Ezzat et al 2004</xref>]. Thus, it is possible for two pituitary tumors, especially prolactinomas, to occur in a family by chance. Instances of phenocopies in families with an <italic toggle="yes">AIP</italic> pathogenic variant have been documented [<xref ref-type="bibr" rid="ipa.REF.vierimaa.2006.1228">Vierimaa et al 2006</xref>, <xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al 2010</xref>].</p>
          <p><bold>Other.</bold> In addition to pituitary adenomas, numerous space-occupying lesions can occur in the pituitary fossa [<xref ref-type="bibr" rid="ipa.REF.saeger.2007.203">Saeger et al 2007</xref>]. The most common space-occupying lesions after pituitary adenomas are craniopharyngiomas which cause symptoms by compressing the normal pituitary, resulting in hormonal deficiencies and mass effects on the surrounding tissues and brain.</p>
        </sec>
      </sec>
      <sec id="ipa.Management_1">
        <title>Management</title>
        <sec id="ipa.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs of an individual with <italic toggle="yes">AIP</italic>-related FIPA, the following evaluations are recommended (for details see <xref ref-type="bibr" rid="ipa.REF.katznelson.2011">Katznelson et al [2011]</xref>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.aace.com/files/acromegaly-guidelines.pdf">full text</ext-link>). Note: The evaluation may have to be individualized depending on the presentation.</p>
          <list list-type="bullet">
            <list-item>
              <p>Detailed personal history, including findings that may be consistent with the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p>A growth hormone-secreting tumor (stature in relation to the rest of the family, change in facial appearance, change in shoe size, problems with ring sizes, headache, excessive sweating, joint pains, carpal tunnel syndrome)</p>
                </list-item>
                <list-item>
                  <p>A prolactinoma (menstrual history, galactorrhea, infertility, low libido, impotence)</p>
                </list-item>
                <list-item>
                  <p>A non-functioning pituitary adenoma and mass effects (headache, lack of other pituitary hormones, visual field problems)</p>
                </list-item>
                <list-item>
                  <p>Thyrotropinoma (hyperthyroidism with non-suppressed TSH)</p>
                </list-item>
                <list-item>
                  <p>Corticotropinoma with Cushing disease (truncal obesity, striae, muscle weakness, thin skin, diabetes mellitus, hypertension)</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Review of serial photographs over time to help identify the onset of acromegalic or cushingoid changes if present at the time of diagnosis</p>
            </list-item>
            <list-item>
              <p>Measurement of parental heights</p>
            </list-item>
            <list-item>
              <p>Clinical examination including measurement of height and documentation of presence or absence of features consistent with the endocrine disorders acromegaly, pituitary gigantism, Cushing disease, thyrotoxicosis</p>
            </list-item>
            <list-item>
              <p>Visual field evaluation</p>
            </list-item>
            <list-item>
              <p>Basal pituitary function including: spot GH, IGF-1; prolactin; LH, FSH, testosterone/estradiol; TSH, fT4; 9 a.m. cortisol</p>
            </list-item>
            <list-item>
              <p>Glucose tolerance test (GTT) in persons with findings of acromegaly to identify abnormal GH dynamics. In addition, about 25% of persons with acromegaly have a diabetic GTT. Assess ACTH reserve if necessary.</p>
            </list-item>
            <list-item>
              <p>In adults with acromegaly, colonoscopy at age 40 years with further surveillance at three- to ten-year intervals depending on the presence/absence of adenomas in the initial colonoscopy and IGF-1 levels [<xref ref-type="bibr" rid="ipa.REF.cairns.2010.666">Cairns et al 2010</xref>]</p>
            </list-item>
            <list-item>
              <p>Pituitary MRI to detect the size and extent of a tumor, if one is suspected</p>
            </list-item>
            <list-item>
              <p>Consultation with specialists in endocrinology</p>
            </list-item>
            <list-item>
              <p>Consultation with specialists in medical genetics to obtain detailed family history (of possible pituitary problems, unusual stature, fertility problems, and/or early death)</p>
            </list-item>
          </list>
        </sec>
        <sec id="ipa.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>While there is experience with treating pituitary adenomas in symptomatic persons with FIPA, there is little experience in the management and treatment of persons identified prospectively through clinical screening due to family history of FIPA and/or presence of a heterozygous <italic toggle="yes">AIP</italic> germline pathogenic variant. The following recommendations are based on those of <xref ref-type="bibr" rid="ipa.REF.biller.2008.2454">Biller et al [2008]</xref>, <xref ref-type="bibr" rid="ipa.REF.jaffe.2006.317">Jaffe [2006]</xref>, <xref ref-type="bibr" rid="ipa.REF.katznelson.2011">Katznelson et al [2011]</xref>, and <xref ref-type="bibr" rid="ipa.REF.melmed.2011.273">Melmed et al [2011]</xref>.</p>
          <p>Pituitary adenomas can be treated by surgery, medical therapy, and/or radiotherapy.</p>
          <p>Adenomas in persons with FIPA, especially those with <italic toggle="yes">AIP</italic>-related FIPA, are aggressive. Surgery is usually performed, but often does not fully control the tumor. Transsphenoidal surgery has been performed for large adenomas, while microadenomas with normal clinical and biochemistry findings are monitored closely [<xref ref-type="bibr" rid="ipa.REF.chahal.2011.43">Chahal et al 2011</xref>]. Large tumors, especially those recurring after surgery, may require radiotherapy when the tumor invades neighboring anatomic structures (such as the cavernous sinus).</p>
          <p><bold>Somatotropinomas</bold>, particularly in persons with a germline <italic toggle="yes">AIP</italic> pathogenic variant, often do not respond to medical therapy with somatostatin analogs. <xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al [2010]</xref> showed no tumor shrinkage in <italic toggle="yes">AIP</italic>-related adenomas and significantly lower reductions in GH secretion (40% vs 75%) and IGF-1 secretion (47% and 56%); in these instances growth hormone receptor antagonist therapy could be initiated [<xref ref-type="bibr" rid="ipa.REF.leontiou.2008.2390">Leontiou et al 2008</xref>, <xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al 2010</xref>].</p>
          <p>Radiotherapy (conventional or radiosurgery) is an option for treating growing adenomas, for which repeat surgery is unlikely to control hormone levels.</p>
          <p><bold>Prolactinomas</bold> are usually treated with dopamine agonist therapy (cabergoline being the drug of choice), which can result in tumor regression or in some cases disappearance of detectable lesions. No data suggest that FIPA-associated prolactinomas would respond less favorably to dopamine agonist therapy than do sporadic tumors; however, <xref ref-type="bibr" rid="ipa.REF.daly.2010.e373">Daly et al [2010]</xref> suggested that prolactinomas in <italic toggle="yes">AIP-</italic>related FIPA appear to be aggressive and difficult to treat. Persons with <italic toggle="yes">AIP-</italic>related FIPA and a macroprolactinoma (diameter &#x0003e;10 mm) often undergo surgery.</p>
          <p><bold>NFPAs</bold> are treated with surgery and, if necessary, radiotherapy. They usually do not respond to traditional somatostatin analogs despite the presence of somatostatin receptors and an often good response in vitro. Dopamine agonist therapy has been tried in some cases. Timely diagnosis, prediction of long-term outcome, and treatment of NFPAs remain a challenge for endocrinologists [<xref ref-type="bibr" rid="ipa.REF.korbonits.2009.123">Korbonits &#x00026; Carlsen 2009</xref>].</p>
          <p>Temozolomide has been successfully used for the treatment of a few aggressive pituitary adenomas; however, there is no experience with its use in persons with <italic toggle="yes">AIP</italic>-related FIPA.</p>
          <p>The increased burden of GH secretion and IGF-1 secretion (defined as the level and duration of increased hormone levels) observed in those with acromegaly is associated with an increased risk for cardiovascular, cerebrovascular, and metabolic complications [<xref ref-type="bibr" rid="ipa.REF.jayasena.2011.220">Jayasena et al 2011</xref>]. Individuals with long-standing acromegaly often have cardiovascular and rheumatologic/orthopedic complications, which need to be treated accordingly.</p>
        </sec>
        <sec id="ipa.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Tumor size, surgery, and/or radiotherapy can cause hypopituitarism, which needs careful expert follow up.</p>
          <p>Persons on glucocorticoid replacement therapy need to increase their steroid dose when ill or stressed.</p>
        </sec>
        <sec id="ipa.Surveillance">
          <title>Surveillance</title>
          <p>No guidelines regarding surveillance of persons with <italic toggle="yes">AIP</italic>-related FIPA have been established. The following recommendations are based on the authors&#x02019; personal experience with more than 200 persons with symptomatic or asymptomatic <italic toggle="yes">AIP</italic>-related FIPA.</p>
          <p><bold>Persons with <italic toggle="yes">AIP</italic>-related FIPA who have had a pituitary adenoma.</bold> The following are recommended to monitor for recurrence of the previous adenoma and development of new adenomas.</p>
          <list list-type="bullet">
            <list-item>
              <p>Yearly clinical assessment and basal pituitary function (IGF-1, spot GH, prolactin, LH/FSH, estradiol/testosterone, TSH, fT4, morning cortisol) and if necessary dynamic testing (e.g., glucose tolerance test, insulin tolerance test) to evaluate for hormone excess or deficiency</p>
            </list-item>
            <list-item>
              <p>Repeat pituitary MRI. Note: Frequency depends on clinical status, previous extent of the tumor, and treatment modality.</p>
            </list-item>
          </list>
          <p><bold>Persons with acromegaly.</bold> Follow established guidelines regarding clinical monitoring for related complications including diabetes mellitus, hypertension, osteoarthritis, and colon cancer.</p>
          <p><bold>Persons with hypogonadism.</bold> Follow established guidelines. Because long-standing untreated hypogonadism may result in the early onset of osteoporosis, bone density needs to be assessed at baseline and if necessary monitored with DEXA scanning.</p>
          <p><bold>Persons with an <italic toggle="yes">AIP</italic> pathogenic variant and no history of pituitary adenomas.</bold> Recommendations follow. Note, however, that long-term experience with asymptomatic <italic toggle="yes">AIP</italic> heterozygotes is limited; more data are needed to develop appropriate future guidelines.</p>
          <p>In a family in which an <italic toggle="yes">AIP</italic> pathogenic variant has been identified, relatives who have the family-specific <italic toggle="yes">AIP</italic> pathogenic variant or who have not been tested:</p>
          <p>
            <bold>Adults</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Baseline<italic toggle="yes">.</italic> Clinical assessment, pituitary function tests (IGF-1, prolactin, estradiol/testosterone, LH, FSH, and fT4), and pituitary MRI</p>
            </list-item>
            <list-item>
              <p>Thereafter</p>
              <list list-type="bullet">
                <list-item>
                  <p>Perform annual clinical assessment and pituitary function tests.</p>
                </list-item>
                <list-item>
                  <p>Consider repeating a pituitary MRI every five years if clinical findings and pituitary function tests remain normal.</p>
                </list-item>
                <list-item>
                  <p>Consider discontinuing monitoring about age 50 years, after which the likelihood of developing new pituitary adenomas is low.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>
            <bold>Children</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Yearly beginning at age four years</p>
              <list list-type="bullet">
                <list-item>
                  <p>Measure height and weight with calculation of height velocity. Document pubertal development, Tanner stages</p>
                </list-item>
                <list-item>
                  <p>Perform pituitary function tests (as for adults).</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Perform baseline pituitary MRI at about age ten years.</p>
            </list-item>
            <list-item>
              <p>Consider repeating the pituitary MRI every five years if clinical and pituitary function tests remain normal.</p>
            </list-item>
          </list>
        </sec>
        <sec id="ipa.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to offer molecular genetic testing to at-risk relatives if the pathogenic variant has been identified in an affected family member so that morbidity and mortality can be reduced by early diagnosis and treatment.</p>
          <p>See <xref ref-type="sec" rid="ipa.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="ipa.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Pregnancy may increase the size of a growth hormone-secreting adenoma or a prolactin-secreting adenoma (especially macroadenomas); thus, a pregnant woman with pituitary macroadenoma is at risk of developing visual field defects. In each trimester it is appropriate to inquire about headaches and perform visual field testing.</p>
        </sec>
        <sec id="ipa.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>A study that is actively ascertaining individuals with FIPA or childhood-onset pituitary adenoma is listed in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT00461188?term=NCT00461188&#x00026;rank=1">ClinicalTrials.gov</ext-link>.</p>
          <p>Growth hormone receptor antagonists block the action of endogenous growth hormone, thereby controlling disease manifestations such as headaches, soft tissue enlargement, diabetes mellitus, hypertension, and high IGF-1 levels. A growth hormone receptor antagonist has been used successfully in persons with <italic toggle="yes">AIP</italic>-related FIPA and acromegaly and pituitary gigantism [<xref ref-type="bibr" rid="ipa.REF.goldenberg.2008.2953">Goldenberg et al 2008</xref>; Author, personal observation]. Although growth hormone receptor antagonists are currently not licensed for pediatric use, several case reports have shown their effectiveness, especially when IGF-1 levels need to be reduced immediately to prevent abnormally rapid growth [<xref ref-type="bibr" rid="ipa.REF.higham.2010.280">Higham et al 2010</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ClinicalTrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="ipa.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="ipa.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">AIP</italic>-related familial isolated pituitary adenoma (<italic toggle="yes">AIP</italic>-related FIPA) is inherited in an autosomal dominant manner with reduced penetrance.</p>
        </sec>
        <sec id="ipa.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Almost all individuals reported to date with <italic toggle="yes">AIP</italic>-related FIPA have a parent who is also heterozygous for the <italic toggle="yes">AIP</italic> pathogenic variant [<xref ref-type="bibr" rid="ipa.REF.chahal.2010.419">Chahal et al 2010</xref>, <xref ref-type="bibr" rid="ipa.REF.stratakis.2010.457">Stratakis et al 2010</xref>]. Because of reduced penetrance, the parent may not be affected.</p>
            </list-item>
            <list-item>
              <p>If the disease-predisposing allelic variant found in the proband cannot be detected in leukocyte DNA of either parent, two possible explanations are germline mosaicism in a parent or <italic toggle="yes">de novo</italic> mutation in the proband, assuming paternity is as stated. Although no instances of germline mosaicism have been reported, it remains a possibility.</p>
            </list-item>
            <list-item>
              <p>As not all simplex <italic toggle="yes">AIP</italic>-related FIPA cases (i.e., a single occurrence in a family) have been evaluated sufficiently to determine if the pathogenic variant was <italic toggle="yes">de novo</italic>, the proportion of <italic toggle="yes">AIP</italic>-related FIPA resulting from <italic toggle="yes">de novo</italic>
<italic toggle="yes">AIP</italic> mutation is unknown. However, this is likely to be low: to date, only one case of proven <italic toggle="yes">de novo</italic> mutation has been reported in an individual with a childhood-onset corticotroph adenoma [<xref ref-type="bibr" rid="ipa.REF.stratakis.2010.457">Stratakis et al 2010</xref>].</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with <italic toggle="yes">AIP</italic>-related FIPA include molecular genetic testing for the <italic toggle="yes">AIP</italic> pathogenic variant identified in the proband. Evaluation of parents may determine that one is heterozygous for an <italic toggle="yes">AIP</italic> pathogenic variant but has escaped previous diagnosis because of a milder phenotypic presentation or reduced penetrance. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>If a parent of the proband is affected or has an <italic toggle="yes">AIP</italic> pathogenic variant, the risk to the sibs of inheriting the pathogenic variant is 50%.</p>
            </list-item>
            <list-item>
              <p>The sibs of a proband with clinically unaffected parents are still at increased risk of inheriting the pathogenic variant because of the possibility of reduced penetrance in a parent.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low, but greater than that of the general population because of the possibility of germline mosaicism. No instances of germline mosaicism have been reported to date.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual heterozygous for an <italic toggle="yes">AIP</italic> pathogenic variant has a 50% chance of inheriting the pathogenic variant.</p>
          <p>
            <bold>Other family members</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to other family members depends on the status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent is heterozygous for an <italic toggle="yes">AIP</italic> pathogenic variant, his or her family members may be at risk for <italic toggle="yes">AIP</italic>-related FIPA.</p>
            </list-item>
          </list>
        </sec>
        <sec id="ipa.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="ipa.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with an autosomal dominant condition has the pathogenic variant, it is possible that mutation occurred <italic toggle="yes">de novo</italic> in the proband. However, possible non-medical explanations include alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could be considered.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="ipa.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the pathogenic variant in <italic toggle="yes">AIP</italic> has been identified in the family, prenatal diagnosis for pregnancies at increased risk may be available through laboratories offering testing for this gene or custom prenatal testing.</p>
          <p>As <italic toggle="yes">AIP</italic>-related FIPA demonstrates reduced penetrance, the finding of a pathogenic variant in <italic toggle="yes">AIP</italic> prenatally does not allow accurate prediction of a tumor, the adenoma type, age of onset, prognosis, or availability of and/or outcome of treatment.</p>
          <p>Requests for prenatal testing for conditions which (like familial isolated pituitary adenomas) do not affect intellect and have some treatment available are rare. In addition, the penetrance, though not yet adequately studied, is thought to be reduced in most families. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although decisions about prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the pathogenic variant has been identified.</p>
        </sec>
      </sec>
      <sec id="ipa.Resources">
        <title>Resources</title>
      </sec>
      <sec id="ipa.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">AIP</italic> comprises six exons encoding a 330-amino acid protein. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="ipa" object-id="ipa.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Variants of uncertain significance.</bold> The variant c.47G&#x0003e;A (p.Arg16His), identified in a few simplex cases of acromegaly (including some childhood-onset cases), was also found in three of 360 controls [<xref ref-type="bibr" rid="ipa.REF.cazabat.2007.1">Cazabat et al 2007</xref>, <xref ref-type="bibr" rid="ipa.REF.daly.2007.1891">Daly et al 2007</xref>, <xref ref-type="bibr" rid="ipa.REF.georgitsi.2007a.4101">Georgitsi et al 2007a</xref>, <xref ref-type="bibr" rid="ipa.REF.tichomirowa.2011.509">Tichomirowa et al 2011</xref>]. It was identified in 0.3% of European Americans and 0.08% of African Americans in the general population. An in vitro functional study of loss of binding to one of the partners of AIP (phosphodiesterase [PDE] subtype 4A5) did not show a significant functional change [<xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al 2010</xref>]. Furthermore, in a family with FIPA the c.47G&#x0003e;A (p.Arg16His) variant did not segregate with pituitary adenomas [<xref ref-type="bibr" rid="ipa.REF.guaraldi.2011.55">Guaraldi &#x00026; Salvatori 2011</xref>].</p>
        <p>The variant c.145G&#x0003e;A (p.Val49Met), reported in one simplex case of gigantism, did not show loss of heterozygosity [<xref ref-type="bibr" rid="ipa.REF.iwata.2007.499">Iwata et al 2007</xref>] or loss of binding to one of the partners of AIP (phosphodiesterase [PDE] subtype 4A5) [<xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al 2010</xref>]. Of note, loss of in vitro PDE binding does not necesserily correspond to clinically important loss of function; however, few functional tests for AIP are currently available and none has proven clinical relevance.</p>
        <p>The variant c.896C&#x0003e;T (p.Ala299Val) was reported in a simplex case of acromegaly [<xref ref-type="bibr" rid="ipa.REF.georgitsi.2007a.4101">Georgitsi et al 2007a</xref>] and in compound heterozygous asymptomatic persons whose other <italic toggle="yes">AIP</italic> allele has the p.Arg304Ter pathogenic truncating variant. The c.896C&#x0003e;T variant is unlikely to reduce the function of the AIP protein significantly, as biallelic inactivation of <italic toggle="yes">AIP</italic> in humans may be an embryonic lethal event, as was demonstrated in mice with a complete <italic toggle="yes">Aip</italic> knockout.</p>
        <p><bold>Pathogenic allelic variants.</bold> About 50 different <italic toggle="yes">AIP</italic> pathogenic variants have been reported, including nonsense, missense, frame shift, and splice site variants, intragenic deletions and insertions, and deletions of one or more exons. See <xref ref-type="table" rid="ipa.T.selected_aip_allelic_variants">Table 3</xref>, <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="ipa-Table4.pdf" content-type="local-data">Table 4</inline-supplementary-material> (pdf).</p>
        <p>Most pathogenic missense variants affect the TPR (tetratricopeptide repeat) (see <bold>Normal gene product</bold>) domains or the C-terminal alpha-helix. This supports the earlier evidence that the TPR domains and the last five C-terminal amino acids are important for the activity of AIP [<xref ref-type="bibr" rid="ipa.REF.petrulis.2002.25">Petrulis &#x00026; Perdew 2002</xref>].</p>
        <p>Recurrent <italic toggle="yes">AIP</italic> pathogenic variants include:</p>
        <list list-type="bullet">
          <list-item>
            <p>p.Arg304Ter or p.Arg304Gln in several independent families and several simplex cases. Out of the several individuals with the p.Arg304Ter variant, two independent clusters (in Ireland and Italy) were shown result from a founder effect [<xref ref-type="bibr" rid="ipa.REF.occhi.2010.800">Occhi et al 2010</xref>, <xref ref-type="bibr" rid="ipa.REF.chahal.2011.43">Chahal et al 2011</xref>].</p>
          </list-item>
          <list-item>
            <p>p.Arg81Ter in two families</p>
          </list-item>
          <list-item>
            <p>p.Arg271Trp in two families and a simplex case of pituitary gigantism</p>
          </list-item>
          <list-item>
            <p>c.807C&#x0003e;T in one family and three simplex cases</p>
          </list-item>
          <list-item>
            <p>c.805_825dup (p.Phe269_His275dup) segmental duplication, identified in five apparently independent families (Note: This duplication is detectable by sequence analysis.)</p>
          </list-item>
          <list-item>
            <p>p.Gln14Ter in a few families and several simplex cases from Finland, suggesting the presence of a founder mutation</p>
          </list-item>
        </list>
        <table-wrap id="ipa.T.selected_aip_allelic_variants" position="anchor" orientation="portrait">
          <label>Table 3. </label>
          <caption>
            <p>Selected <italic toggle="yes">AIP</italic> Allelic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Class of Variant Allele</th>
                <th id="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                <th id="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Uncertain significance</bold>
                </td>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.47G&#x0003e;A</td>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg16His</td>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_4" rowspan="11" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_003977.2">NM_003977.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_003968.2">NP_003968.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.145G&#x0003e;A</td>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Val49Met</td>
              </tr>
              <tr>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.896C&#x0003e;T</td>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala299Val</td>
              </tr>
              <tr>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_1" rowspan="8" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Pathogenic</bold>
                </td>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.40C&#x0003e;T</td>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gln14Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.241C&#x0003e;T</td>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg81Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.807C&#x0003e;T</td>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.=&#x000a0;<sup>1</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.721A&#x0003e;G</td>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Lys241Glu</td>
              </tr>
              <tr>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.805_825dup</td>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Phe269_His275dup</td>
              </tr>
              <tr>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.811C&#x0003e;T</td>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg271Trp</td>
              </tr>
              <tr>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.911G&#x0003e;A</td>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg304Gln</td>
              </tr>
              <tr>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.910C&#x0003e;T</td>
                <td headers="hd_h_ipa.T.selected_aip_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg304Ter</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="ipa.TF.3.1">
              <label>1. </label>
              <p>p.= designates that protein has not been analyzed, but no change is expected.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">AIP</italic> is a tumor suppressor gene [<xref ref-type="bibr" rid="ipa.REF.leontiou.2008.2390">Leontiou et al 2008</xref>]. Its protein product, AIP, previously known as hepatitis B virus (HBV) X-associated protein (XAP2) or aryl hydrocarbon receptor (AhR)-associated protein (ARA9), is a 330-amino acid 37-kd protein [<xref ref-type="bibr" rid="ipa.REF.kuzhandaivelu.1996.4741">Kuzhandaivelu et al 1996</xref>, <xref ref-type="bibr" rid="ipa.REF.carver.1997.11452">Carver &#x00026; Bradfield 1997</xref>]. The C-terminal end of the protein has three tetratricopeptide repeats (TPRs) and a final alpha-helix. The three TPR domains are degenerate sequences of 34 amino acids comprising two antiparallel helices that play a crucial role in mediating the protein-protein interactions of AIP [<xref ref-type="bibr" rid="ipa.REF.kazlauskas.2002.11795">Kazlauskas et al 2002</xref>].</p>
        <p><bold>Abnormal gene product.</bold> The majority (70%) of <italic toggle="yes">AIP</italic> variants result in, or predict, a truncated protein. Many of the pathogenic missense variants affect structurally important conserved amino acids of the TPR structure [<xref ref-type="bibr" rid="ipa.REF.vargiolu.2009.2571">Vargiolu et al 2009</xref>, <xref ref-type="bibr" rid="ipa.REF.igreja.2010.950">Igreja et al 2010</xref>, <xref ref-type="bibr" rid="ipa.REF.cai.2011.e25201">Cai et al 2011</xref>]. Clinical data and functional studies both indicate a tumor suppressor role for AIP.</p>
      </sec>
      <sec id="ipa.References">
        <title>References</title>
        <sec id="ipa.Published_GuidelinesConsensus_Statem">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="ipa.Published_GuidelinesConsensus_Statem.reflist0">
            <ref id="ipa.REF.katznelson.2011">
              <mixed-citation publication-type="webpage">Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.aace.com/files/acromegaly-guidelines.pdf">online</ext-link> (pdf). 2011. Accessed 6-16-15.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="ipa.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="ipa.Literature_Cited.reflist0">
            <ref id="ipa.REF.agarwal.2009.1826">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Agarwal</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mateo</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marx</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>94</volume>
                <fpage>1826</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">19141585</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.biller.2008.2454">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Biller</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grossman</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stewart</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melmed</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertagna</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertherat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buchfelder</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colao</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermus</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hofland</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klibanski</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacroix</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindsay</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newell-Price</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nieman</surname>
                    <given-names>LK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petersenn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sonino</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stalla</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swearingen</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vance</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wass</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boscaro</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>93</volume>
                <fpage>2454</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">18413427</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.cai.2011.e25201">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cai</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kramarova</surname>
                    <given-names>TV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berg</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korbonits</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pongratz</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>The immunophilin-like protein XAP2 is a negative regulator of estrogen signaling through interaction with estrogen receptor &#x003b1;.</article-title>
                <source>PLoS One.</source>
                <volume>6</volume>
                <fpage>e25201</fpage>
                <pub-id pub-id-type="pmid">21984905</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.cain.2010.681">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cain</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miljic</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Popovic</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korbonits</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Role of the aryl hydrocarbon receptor-interacting protein in familial isolated pituitary adenoma.</article-title>
                <source>Expert Rev Endocrinol Metab.</source>
                <year>2010</year>
                <volume>5</volume>
                <fpage>681</fpage>
                <lpage>95</lpage>
              </element-citation>
            </ref>
            <ref id="ipa.REF.cairns.2010.666">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cairns</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scholefield</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steele</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunlop</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eaden</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rutter</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atkin</surname>
                    <given-names>WP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saunders</surname>
                    <given-names>BP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucassen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jenkins</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fairclough</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woodhouse</surname>
                    <given-names>CR</given-names>
                  </name>
                  <collab>British Society of Gastroenterology</collab>
                </person-group>
                <article-title>Association of Coloproctology for Great Britain and Ireland. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002).</article-title>
                <source>Gut.</source>
                <year>2010</year>
                <month>May</month>
                <volume>59</volume>
                <issue>5</issue>
                <fpage>666</fpage>
                <lpage>89</lpage>
                <pub-id pub-id-type="pmid">20427401</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.carver.1997.11452">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carver</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bradfield</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Ligand-dependent interaction of the aryl hydrocarbon receptor with a novel immunophilin homolog in vivo.</article-title>
                <source>J Biol Chem.</source>
                <volume>272</volume>
                <fpage>11452</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">9111057</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.cazabat.2011.1973">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cazabat</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouligand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chanson</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>AIP mutation in pituitary adenomas.</article-title>
                <source>N Engl J Med.</source>
                <volume>364</volume>
                <fpage>1973</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">21591954</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.cazabat.2009.132">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cazabat</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guillaud-Bataille</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertherat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raffin-Sanson</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas.</article-title>
                <source>Horm Res.</source>
                <volume>71</volume>
                <fpage>132</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">19188737</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.cazabat.2007.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cazabat</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lib&#x000e8;</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perlemoine</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ren&#x000e9;-Corail</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burnichon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimenez-Roqueplo</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dupasquier-Fediaevsky</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertagna</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clauser</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chanson</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertherat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raffin-Sanson</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas.</article-title>
                <source>Eur J Endocrinol.</source>
                <volume>157</volume>
                <fpage>1</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17609395</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.chahal.2010.419">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chahal</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapple</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frohman</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grossman</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korbonits</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA).</article-title>
                <source>Trends Endocrinol Metab.</source>
                <volume>21</volume>
                <fpage>419</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">20570174</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.chahal.2011.43">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chahal</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stals</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Unterl&#x000e4;nder</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balding</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Besser</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atkinson</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrison</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howlett</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orme</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akker</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abel</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grossman</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burger</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korbonits</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>AIP mutation in pituitary adenomas in the 18th century and today.</article-title>
                <source>N Engl J Med.</source>
                <volume>364</volume>
                <fpage>43</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">21208107</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.daly.2006.4769">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Daly</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rixhon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adam</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dempegioti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tichomirowa</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beckers</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>91</volume>
                <fpage>4769</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">16968795</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.daly.2010.e373">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Daly</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tichomirowa</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrossians</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heli&#x000f6;vaara</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaffrain-Rea</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barlier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naves</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ebeling</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karhu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raappana</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazabat</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Menis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monta&#x000f1;ana</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raverot</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weil</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sane</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maiter</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neggers</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaneva</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tabarin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verrua</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eloranta</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vierimaa</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salmela</surname>
                    <given-names>PI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emy</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toledo</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabat&#x000e9;</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Popelier</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salvatori</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jennings</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Long&#x000e1;s</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labarta Aizp&#x000fa;n</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Georgitsi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschke</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ronchi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valimaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saloranta</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Herder</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cozzi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guitelman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magri</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lagonigro</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halaby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corman</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagelstein</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanbellinghen</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barra</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimenez-Roqueplo</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cameron</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borson-Chazot</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holdaway</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toledo</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stalla</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zacharieva</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertherat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brue</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bours</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chanson</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aaltonen</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beckers</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>95</volume>
                <fpage>E373</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">20685857</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.daly.2007.1891">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Daly</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanbellinghen</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khoo</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaffrain-Rea</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naves</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guitelman</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emy</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimenez-Roqueplo</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tamburrano</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raverot</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barlier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Herder</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penfornis</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ciccarelli</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estour</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lecomte</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gatta</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabre</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabat&#x000e9;</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertagna</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia Basavilbaso</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stalldecker</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colao</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferolla</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>W&#x000e9;meau</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caron</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sadoul</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oneto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Archambeaud</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calender</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinilnikova</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monta&#x000f1;ana</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cavagnini</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hana</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delettieres</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luccio-Camelo</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basso</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohmer</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brue</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bours</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teh</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beckers</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>92</volume>
                <fpage>1891</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17244780</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.de_groot.2010">
              <mixed-citation publication-type="book">De Groot LJ, Jameson JL. <italic toggle="yes">Endocrinology</italic>. Philadelphia, PA: Elsevier; 2010.</mixed-citation>
            </ref>
            <ref id="ipa.REF.ezzat.2004.613">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ezzat</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asa</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Couldwell</surname>
                    <given-names>WT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barr</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dodge</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vance</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCutcheon</surname>
                    <given-names>IE</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>The prevalence of pituitary adenomas: a systematic review.</article-title>
                <source>Cancer.</source>
                <volume>101</volume>
                <fpage>613</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15274075</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.fernandez.2010.377">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fernandez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karavitaki</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wass</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <volume>72</volume>
                <fpage>377</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">19650784</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.georgitsi.2008a.621">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Georgitsi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Menis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cannav&#x000f2;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e4;kinen</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuppurainen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pauletto</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Curt&#x000f2;</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weil</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschke</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zielinski</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wasik</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lubinski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vahteristo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karhu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aaltonen</surname>
                    <given-names>LA</given-names>
                  </name>
                </person-group>
                <year>2008a</year>
                <article-title>Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas.</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <volume>69</volume>
                <fpage>621</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18410548</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.georgitsi.2008b.4146">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Georgitsi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heli&#x000f6;vaara</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschke</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tischkowitz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vierimaa</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salmela</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sane</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Menis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cannav&#x000f2;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;ndogdu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucassen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Izatt</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aylwin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bano</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hodgson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karhu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aaltonen</surname>
                    <given-names>LA</given-names>
                  </name>
                </person-group>
                <year>2008b</year>
                <article-title>Large genomic deletions in AIP in pituitary adenoma predisposition.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>93</volume>
                <fpage>4146</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">18628514</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.georgitsi.2007a.4101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Georgitsi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raitila</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karhu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuppurainen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e4;kinen</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vierimaa</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschke</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saeger</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Luijt</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sane</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robledo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Menis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weil</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wasik</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zielinski</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucewicz</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lubinski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Launonen</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vahteristo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aaltonen</surname>
                    <given-names>LA</given-names>
                  </name>
                </person-group>
                <year>2007a</year>
                <article-title>Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations.</article-title>
                <source>Proc Natl Acad Sci U S A.</source>
                <volume>104</volume>
                <fpage>4101</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">17360484</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.georgitsi.2007b.3321">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Georgitsi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raitila</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karhu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Luijt</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aalfs</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sane</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vierimaa</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e4;kinen</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuppurainen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschke</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimm</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;ndogdu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucassen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tischkowitz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Izatt</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aylwin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bano</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hodgson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Menis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Launonen</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vahteristo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aaltonen</surname>
                    <given-names>LA</given-names>
                  </name>
                </person-group>
                <year>2007b</year>
                <article-title>Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>92</volume>
                <fpage>3321</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">17519308</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.goldenberg.2008.2953">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goldenberg</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Racine</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Degnan</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chandler</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barkan</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>93</volume>
                <fpage>2953</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18492755</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.guaraldi.2011.55">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guaraldi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salvatori</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Familial isolated pituitary adenomas: from genetics to therapy.</article-title>
                <source>Clin Transl Sci.</source>
                <volume>4</volume>
                <fpage>55</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">21348957</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.higham.2010.280">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Higham</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emy</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferone</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finke</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laurberg</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Main</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maffei</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minuto</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rainegard</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salzgeber</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koltowska-Haggstrom</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trainer</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <article-title>Treatment experience in 11 patients with gigantism.</article-title>
                <source>Endocrine Abstracts.</source>
                <year>2010</year>
                <volume>21</volume>
                <fpage>280</fpage>
              </element-citation>
            </ref>
            <ref id="ipa.REF.horvath.2008.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Horvath</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stratakis</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors.</article-title>
                <source>Rev Endocr Metab Disord.</source>
                <volume>9</volume>
                <fpage>1</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">18200440</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.igreja.2010.950">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Igreja</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chahal</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolger</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Srirangalingam</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guasti</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapple</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trivellin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gueorguiev</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guegan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stals</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khoo</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grossman</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korbonits</surname>
                    <given-names>M</given-names>
                  </name>
                  <collab>International FIPA Consortium</collab>
                </person-group>
                <year>2010</year>
                <article-title>Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families.</article-title>
                <source>Hum Mutat.</source>
                <volume>31</volume>
                <fpage>950</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">20506337</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.iwata.2007.499">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Iwata</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizusawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Golam</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sano</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshimoto</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas.</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <volume>66</volume>
                <fpage>499</fpage>
                <lpage>502</lpage>
                <pub-id pub-id-type="pmid">17371465</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.jaffe.2006.317">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jaffe</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Clinically non-functioning pituitary adenoma.</article-title>
                <source>Pituitary.</source>
                <volume>9</volume>
                <fpage>317</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">17082898</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.jayasena.2011.220">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jayasena</surname>
                    <given-names>CN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comninos</surname>
                    <given-names>AN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donaldson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meeran</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dhillo</surname>
                    <given-names>WS</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <volume>75</volume>
                <fpage>220</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21521288</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.katznelson.2011.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Katznelson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atkinson</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ezzat</surname>
                    <given-names>SZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamrahian</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>KK</given-names>
                  </name>
                  <collab>American Association of Clinical Endocrinologists</collab>
                </person-group>
                <year>2011</year>
                <article-title>American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.</article-title>
                <source>Endocr Pract.</source>
                <volume>17</volume>
                <supplement>Suppl 4</supplement>
                <fpage>1</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">21846616</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.kazlauskas.2002.11795">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kazlauskas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poellinger</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pongratz</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Two distinct regions of the immunophilin-like protein XAP2 regulate dioxin receptor function and interaction with hsp90.</article-title>
                <source>J Biol Chem.</source>
                <volume>277</volume>
                <fpage>11795</fpage>
                <lpage>801</lpage>
                <pub-id pub-id-type="pmid">11805120</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.keil.2008.563">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Keil</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stratakis</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics.</article-title>
                <source>Expert Rev Neurother.</source>
                <volume>8</volume>
                <fpage>563</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">18416659</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.khoo.2009.1057">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Khoo</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pendek</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nickolov</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luccio-Camelo</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newton</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Massie</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petillo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menon</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cameron</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teh</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>SP</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Genome-wide scan identifies novel modifier loci of acromegalic phenotypes for isolated familial somatotropinoma.</article-title>
                <source>Endocr Relat Cancer.</source>
                <volume>16</volume>
                <fpage>1057</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">19443539</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.korbonits.2009.123">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Korbonits</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carlsen</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Recent clinical and pathophysiological advances in non-functioning pituitary adenomas.</article-title>
                <source>Horm Res.</source>
                <volume>71</volume>
                <supplement>Suppl 2</supplement>
                <fpage>123</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">19407508</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.korbonits.2012.351">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Korbonits</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Storr</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>AV</given-names>
                  </name>
                </person-group>
                <article-title>Familial pituitary adenomas - who should be tested for AIP mutations?</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <year>2012</year>
                <volume>77</volume>
                <fpage>351</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22612670</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.kuzhandaivelu.1996.4741">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kuzhandaivelu</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cong</surname>
                    <given-names>YS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inouye</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seto</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>XAP2, a novel hepatitis B virus X-associated protein that inhibits X transactivation.</article-title>
                <source>Nucleic Acids Res.</source>
                <volume>24</volume>
                <fpage>4741</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">8972861</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.leontiou.2008.2390">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leontiou</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gueorguiev</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Spuy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinton</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lolli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hassan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chahal</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Igreja</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jordan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rowe</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stolbrink</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christian</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wray</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bishop-Bailey</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berney</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wass</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Popovic</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro-Oliveira</surname>
                    <given-names>A</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Gadelha</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monson</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akker</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>RN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshimoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwata</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuno</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eguchi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Musat</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flanagan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolger</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapple</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frohman</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grossman</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korbonits</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>93</volume>
                <fpage>2390</fpage>
                <lpage>401</lpage>
                <pub-id pub-id-type="pmid">18381572</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.melmed.2011.273">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Melmed</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casanueva</surname>
                    <given-names>FF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffman</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleinberg</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montori</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlechte</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wass</surname>
                    <given-names>JA</given-names>
                  </name>
                  <collab>Endocrine Society</collab>
                </person-group>
                <year>2011</year>
                <article-title>Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>96</volume>
                <fpage>273</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">21296991</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.naves.2007.383">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Naves</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daly</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanbellinghen</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casulari</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spilioti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magalh&#x000e3;es</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azevedo</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giacomini</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nascimento</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nunes</surname>
                    <given-names>RO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosa</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaffrain-Rea</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bours</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beckers</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene.</article-title>
                <source>Eur J Endocrinol.</source>
                <volume>157</volume>
                <fpage>383</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">17893251</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.occhi.2010.800">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Occhi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaffrain-Rea</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trivellin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Albiger</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ceccato</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Menis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferasin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beckers</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mantero</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scaroni</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>The R304X mutation of the aryl hydrocarbon receptor interacting protein gene in familial isolated pituitary adenomas: Mutational hot-spot or founder effect?</article-title>
                <source>J Endocrinol Invest.</source>
                <volume>33</volume>
                <fpage>800</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">20354355</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.pellegata.2006.15558">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pellegata</surname>
                    <given-names>NS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quintanilla-Martinez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siggelkow</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samson</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bink</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000f6;fler</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fend</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graw</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atkinson</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans.</article-title>
                <source>Proc Natl Acad Sci U S A.</source>
                <volume>103</volume>
                <fpage>15558</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">17030811</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.petrulis.2002.25">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Petrulis</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perdew</surname>
                    <given-names>GH</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>The role of chaperone proteins in the aryl hydrocarbon receptor core complex.</article-title>
                <source>Chem Biol Interact.</source>
                <volume>141</volume>
                <fpage>25</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">12213383</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.saeger.2007.203">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Saeger</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000fc;decke</surname>
                    <given-names>DK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buchfelder</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fahlbusch</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quabbe</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petersenn</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.</article-title>
                <source>Eur J Endocrinol.</source>
                <volume>156</volume>
                <fpage>203</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">17287410</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.stratakis.2010.457">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stratakis</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tichomirowa</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boikos</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azevedo</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lodish</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martari</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verma</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daly</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raygada</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keil</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papademetriou</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drori-Herishanu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horvath</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsang</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nesterova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franklin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanbellinghen</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bours</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salvatori</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beckers</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes.</article-title>
                <source>Clin Genet.</source>
                <volume>78</volume>
                <fpage>457</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">20507346</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.tichomirowa.2011.509">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tichomirowa</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barlier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daly</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaffrain-Rea</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ronchi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaneva</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urban</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrossians</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elenkova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tabarin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desailloud</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maiter</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000fc;rmeyer</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cozzi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theodoropoulou</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sievers</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernabeu</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naves</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabre</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monta&#x000f1;ana</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hana</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halaby</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delemer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aizp&#x000fa;n</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sonnet</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Long&#x000e1;s</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagelstein</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caron</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stalla</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bours</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zacharieva</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brue</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beckers</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas.</article-title>
                <source>Eur J Endocrinol.</source>
                <volume>165</volume>
                <fpage>509</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">21753072</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.vargiolu.2009.2571">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vargiolu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fusco</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurelac</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dirnberger</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumeister</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morra</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melcarne</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rimondini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romeo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonora</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>94</volume>
                <fpage>2571</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19366855</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.vierimaa.2006.1228">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vierimaa</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Georgitsi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehtonen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vahteristo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kokko</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raitila</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuppurainen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ebeling</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salmela</surname>
                    <given-names>PI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschke</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;ndogdu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Menis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e4;kinen</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Launonen</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karhu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aaltonen</surname>
                    <given-names>LA</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Pituitary adenoma predisposition caused by germline mutations in the AIP gene.</article-title>
                <source>Science.</source>
                <volume>312</volume>
                <fpage>1228</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">16728643</pub-id>
              </element-citation>
            </ref>
            <ref id="ipa.REF.villa.2011.347">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Villa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lagonigro</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magri</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koziak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaffrain-Rea</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brauner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouligand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Junier</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Rocco</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sainte-Rose</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beckers</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roux</surname>
                    <given-names>FX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daly</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiovato</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation.</article-title>
                <source>Endocr Relat Cancer.</source>
                <volume>18</volume>
                <fpage>347</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">21450940</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="ipa.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="ipa.Author_Notes">
          <title>Author Notes</title>
          <p><bold>Web site:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fipapatients.org/about/">www.fipapatients.org</ext-link></p>
          <p>The FIPA Patients Web site, established by Dr. Korbonits in collaboration with the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fipapatients.org/fipaconsortium/">FIPA Consortium</ext-link>, is an information resource for patients and families with familial isolated pituitary adenoma. It also provides general information for medical professionals on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fipapatients.org/research/">research</ext-link> in the field of FIPA, including <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fipapatients.org/references/">links to relevant publications</ext-link>.</p>
          <p>The authors welcome comments and inquiries: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="info@fipapatients.org">mailto:info@fipapatients.org</email>.</p>
        </sec>
        <sec id="ipa.Acknowledgments">
          <title>Acknowledgments</title>
          <p>We are grateful to referring colleagues and patients for providing information on this disease. We are grateful for the expert help of Giampaolo Trivellin in the compilation of Table 4.</p>
        </sec>
        <sec id="ipa.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>21 June 2012 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>3 February 2011 (mk) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="ipa.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Relationship between terms used in the past for familial isolated pituitary adenomas (FIPA)PAP = pituitary adenoma predisposition syndromeIFS = Isolated familial somatotropinomas</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ipa-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
